2009
p53 mutations to predict efficacy of alkylating-containing regimen: a metaanalysis of four different clinical trials.
Lehmann-Che J, André F, Desmedt C, Giacchetti S, Sotiriou C, Turpin E, Espié M, Marty M, Piccart M, Pusztai L, De Thé H. p53 mutations to predict efficacy of alkylating-containing regimen: a metaanalysis of four different clinical trials. Cancer Research 2009, 69: 6064. DOI: 10.1158/0008-5472.sabcs-6064.Peer-Reviewed Original ResearchPathologic complete responseAnthracycline-based chemotherapyPCR rateWild-type tumorsP53 wild-type tumorsP53 mutationsType tumorsPredictive valueAnthracycline-containing chemotherapyBreast cancer patientsDifferent clinical trialsDifferent clinical studiesP53 mutant tumorsInvasive tumor cellsDose intensityComplete responseLymph nodesCancer patientsNegative cancersClinical trialsBreast cancerClinical studiesEstrogen receptorTOP trialPatients
2008
Residual specimen cellularity after neoadjuvant chemotherapy for breast cancer
Peintinger F, Kuerer HM, McGuire SE, Bassett R, Pusztai L, Symmans WF. Residual specimen cellularity after neoadjuvant chemotherapy for breast cancer. British Journal Of Surgery 2008, 95: 433-437. PMID: 18161887, DOI: 10.1002/bjs.6044.Peer-Reviewed Original ResearchConceptsResidual tumour cellularityNeoadjuvant chemotherapyBreast-conserving surgeryResidual cellularityBreast cancerTumor cellularityIntraoperative marginsInitial breast-conserving surgeryResidual invasive breast cancerInvasive breast cancerPrimary tumor areaInvasive lobular carcinomaFalse-negative marginsCent of specimensInvasive tumor cellsLobular carcinomaMargin rateChemotherapyPatientsPathology slidesCellularityTumor areaSurgeryTumor cellsCancer